Current Report Filing (8-k)
September 30 2016 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported)
September 27,
2016
Interleukin
Genetics, Inc.
(Exact Name of Registrant as Specified in
Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-32715
|
94-3123681
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
135 Beaver Street Waltham, MA
|
02452
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(781)
398-0700
(Registrant’s Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
ITEM 1.01
|
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
|
On September 27, 2016, Interleukin Genetics,
Inc. (the “Company”) entered into a Third Amendment to Commercial Lease (the “Third Amendment”) with Clematis
LLC (“Lessor”) to amend the Commercial Lease (“Lease”), dated February 13, 2004, between the Company and
the Lessor, as amended on November 18, 2008 and on February 7, 2014. The Third Amendment extends the term of the lease from April
1, 2017 to March 31, 2019.
A
copy
of the Third Amendment is being filed herewith as Exhibit 10.1 and the information contained therein is incorporated by reference
into this Current Report on Form 8-K.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
10.1
|
Third Amendment to Commercial Lease, dated as of September 27, 2016, by and between the Company and Clematis, LLC.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Interleukin
Genetics, Inc
.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
Date: September 30, 2016
|
/s/ Stephen DiPalma
|
|
|
Stephen DiPalma
|
|
|
Interim Chief Financial Officer
|
|
|
(Signature)
|
|